Concepedia

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study

Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha H. Shah, Ronnie Shapira‐Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L. Kindler, José A. López-Martín, Wilson H. Miller,

The Lancet Oncology · 2020 · 2.5K citations · 19 references

Open access

References

19

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

Medicine, Oncology, Treatment Planning +14

Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder et al. · Science · 2015 · 7.9K citations

Medicine, Immunology, Oncology +17

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden

Matthew D. Hellmann, Tudor–Eliade Ciuleanu, Adam Płużański et al. · New England Journal of Medicine · 2018 · 3.1K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

Eliezer M. Van Allen, Diana Miao, Bastian Schilling et al. · Science · 2015 · 3K citations · Full text

Medicine, Cancer Biology, Oncology +17

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurélien Marabelle, Dung T. Le, Paolo A. Ascierto et al. · Journal of Clinical Oncology · 2019 · 3K citations · Full text

Life Sciences, Immunology, Oncology +17